0
Synlogic Therapeutics Banner Image

Synlogic Therapeutics has reached its limit for free report views

Work for Synlogic Therapeutics? Upgrade Your Profile and unlock all your annual reports.

Synlogic Therapeutics

  • Ticker SYBX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Synlogic Therapeutics Logo Image
  • 51-200 Employees
  • Based in Cambridge, Massachusetts
Synlogic is pioneering the development of a novel class of living medicines, Synthetic Biotic medicines, based on its proprietary drug development platform. Synlogic leverages the tools and principles of synthetic biology to genetically engineer beneficial microbes to perform or deliver critical functions missing or damaged due to disease. Synthetic Biotic medicines are designed to actMore locally and have a systemic effect to address disease in patients. Synlogic’s two lead programs, SYNB1020 and SYNB1618, are orally administered and target hyperammonemia as a result of liver damage or genetic disease, and phenylketonuria, respectively. Synlogic is also developing SYNB1891 as an intratumorally-administered Synthetic Biotic medicine for the treatment of cancer. In addition, the company is leveraging the broad potential of its platform to create additional Synthetic Biotic medicines for the treatment of liver disease, as well as inflammatory and immune disorders including Synlogic’s collaboration with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease (IBD).
Synlogic Therapeutics

Most Recent Annual Report

Synlogic Therapeutics MOST RECENT 2020 Annual Report and Form 10K

Report Locked. Synlogic Therapeutics has reached its limit for free report views.

Older/Archived Annual Reports